Integra Lifesciences Holdings (IART) Cash & Equivalents (2009 - 2026)

Integra Lifesciences Holdings has disclosed Cash & Equivalents across 18 years of filings, most recently posting $214.4 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 1.61% year-over-year to $214.4 million; the TTM figure through Jun 2026 stood at $214.4 million (down 1.61% YoY), while the FY2025 annual figure was $235.0 million, down 4.6% from the prior year.
• Cash & Equivalents came in at $214.4 million for Q2 2026 at Integra Lifesciences Holdings, down from $236.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $591.9 million in Q1 2024 to a low of $214.4 million in Q2 2026.
• Average Cash & Equivalents over 5 years is $313.0 million, with a median of $260.1 million recorded in 2023.
• Year-over-year, Cash & Equivalents soared 92.57% in 2024 and slumped 59.6% in 2025.
• Over 5 years, Cash & Equivalents stood at $456.7 million in 2022, then sank by 39.47% to $276.4 million in 2023, then decreased by 10.86% to $246.4 million in 2024, then fell by 4.6% to $235.0 million in 2025, then fell by 8.78% to $214.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $214.4 million in Q2 2026, $236.8 million in Q1 2026, and $235.0 million in Q4 2025.